1. Oral Combination Therapy for T2D

2. SGLT2i Newest Antihyperglycemic Class

3. DPP-4i Mechanism of Action

4. Glycemic Control Algorithm and Goals

5. Combination Therapy SGLT2i Plus DPP-4i

7. Change in HbA1c With Combination Empa and Lina Therapy

8. Why Are Effects of FDCs Not Additive?

9. Percentage of Patients Achieving HbA1c of Less Than 7% With Combination Empa and Lina Therapy

10. Considerations for Combination Therapies in Clinical Practice

11. Percentage of Patients Achieving HbA1c of Less Than 7% With Combination Dapa Plus Saxa Therapy With Metformin

12. Common Side Effects of FDC Components

13. Uptake of FDCs

15. Abbreviations

16. Abbreviations (cont)